Cerebellar High-Grade Glioma: A Translationally Oriented Review of the Literature
Authors:
- Ashley L. B. RaghuARAshley L. B. Raghu
- Jason A. ChenJCJason A. Chen
- Pablo A. ValdesPVPablo A. Valdes
- Walid Ibn EssayedWEWalid Ibn Essayed
- Elizabeth ClausECElizabeth Claus
- Omar ArnaoutOAOmar Arnaout
- Timothy R. SmithTSTimothy R. Smith
- E. Antonio ChioccaECE. Antonio Chiocca
- Pier Paolo PeruzziPPPier Paolo Peruzzi
- Joshua D. BernstockJBJoshua D. Bernstock
Open Access
Abstract
World Health Organization (WHO) grade 4 gliomas of the cerebellum are rare entities whose understanding trails that of their supratentorial counterparts. Like supratentorial high-grade gliomas (sHGG), cerebellar high-grade gliomas (cHGG) preferentially affect males and prognosis is bleak; however, they are more common in a younger population. While current therapy for cerebellar and supratentorial HGG is the same, recent molecular analyses have identified features and subclasses of cerebellar tumors that may merit individualized targeting. One recent series of cHGG included the subclasses of (1) high-grade astrocytoma with piloid features (HGAP, ~31% of tumors); (2) H3K27M diffuse midline glioma (~8%); and (3) isocitrate dehydrogenase (IDH) wildtype glioblastoma (~43%). The latter had an unusually low-frequency of epidermal growth factor receptor (EGFR) and high-frequency of platelet-derived growth factor receptor alpha (PDGFRA) amplification, reflecting a different composition of methylation classes compared to supratentorial IDH-wildtype tumors. These new classifications have begun to reveal insights into the pathogenesis of HGG in the cerebellum and lead toward individualized treatment targeted toward the appropriate subclass of cHGG. Emerging therapeutic strategies include targeting the mitogen-activated protein kinases (MAPK) pathway and PDGFRA, oncolytic virotherapy, and immunotherapy. HGGs of the cerebellum exhibit biological differences compared to sHGG, and improved understanding of their molecular subclasses has the potential to advance treatment.Keywords
This publication has 79 references indexed in Scilit:
- Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomasProceedings of the National Academy of Sciences, 2013
- Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamicsProceedings of the National Academy of Sciences, 2013
- Adult cerebellar glioblastoma cases have different characteristics from supratentorial glioblastomaBrain Tumor Pathology, 2011
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary GlioblastomasClinical Cancer Research, 2009
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- Overexpression of the EGF Receptor and p53 Mutations are Mutually Exclusive in the Evolution of Primary and Secondary GlioblastomasBrain Pathology, 1996
- Epidermal growth factor receptor: An independent predictor of survival in astrocytic tumors given definitive irradiationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1996
- Primary malignant cerebellar astrocytomas in children: A signal for postoperative craniospinal irradiationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1981
- Macrophages in experimental and human brain tumorsJournal of Neurosurgery, 1979